CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payn ...
Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that ...
BioNTech (NasdaqGS:BNTX) cofounders Ugur Sahin and Özlem Türeci are leaving their roles as CEO and Chief Medical Officer.
VetClaw by OpenVet introduces species aware, safety-first clinical workflows designed to help advance the future of ...
Touchlight, in collaboration with New England Biolabs (NEB®), announces the launch of the EnClose™ Cell-free dbDNA™ Synthesis Kit, a new benchtop solution enabling rapid enzymatic production of ...
Harrison Street Asset Management has secured $136 million to refinance Modera Lofts, a 366-unit luxury apartment complex in ...
DFJ Growth and Northzone lead funding round as startup scales AI tools to detect software vulnerabilities amid rising cyber ...
Morning Overview on MSN
Prodrug lipid nanoparticle delivers IDO inhibitor and mRNA to fight tumors
Engineers at the University of Pennsylvania have built a lipid nanoparticle that chemically fuses an IDO-pathway inhibitor ...
Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top candidates in ...
At first glance this was huge news with chemical implications: $300 billion would be an extraordinary investment for a ...
In the case of mRNA cancer vaccines, this false narrative could undermine public confidence in an important tool that may help prevent or treat cancer in the future. Most people likely first heard ...
Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results